Genmab A (GMAB) Retained Earnings (2018 - 2026)

Genmab A (GMAB) has reported Retained Earnings for 9 consecutive years, with $4.4 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings rose 22.87% year-over-year to $4.4 billion; the trailing twelve-month figure through Jun 2026 stood at $4.4 billion (up 22.87% YoY), and the FY2025 full-year result was $4.1 billion, up 20.81% from the prior year.
• Retained Earnings improved to $4.4 billion in Q2 2026 per GMAB's latest filing, from $4.1 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $4.4 billion in Q2 2026 and bottomed at $1.1 billion in Q1 2022.
• Historically, Retained Earnings has averaged $2.4 billion across 5 years, with a median of $1.9 billion in 2024.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings increased 10.25% in 2024, then jumped 114.03% in 2025.
• Over 5 years, Retained Earnings stood at $1.5 billion in 2022, then rose by 21.66% to $1.8 billion in 2023, then increased by 22.61% to $2.2 billion in 2024, then surged by 87.02% to $4.1 billion in 2025, then increased by 7.88% to $4.4 billion in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered $4.4 billion, $4.1 billion, and $4.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.